Advertisement
Advertisement
IMCR
Immunocore Holdings plc - ADR
32.01
USDSponsored
+1.09
+3.52%
Feb 06, 15:59 UTC -5
Closed
After-Market
31.98
-0.03
-0.09%
IMCR Earnings Reports
Positive Surprise Ratio
IMCR beat 12 of 20 last estimates.
60%
Next Report
Date of Next Report
Feb 24, 2026
Estimate for Q4 25 (Revenue/ EPS)
$109.95M
/-$0.23
Implied change from Q3 25 (Revenue/ EPS)
+6.04%
/--
Implied change from Q4 24 (Revenue/ EPS)
+30.82%
/-51.06%
Immunocore Holdings plc - ADR earnings per share and revenue
On Nov 06, 2025, IMCR reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of -0.26 USD, resulting in a 100.00% surprise. Revenue reached 103.69 million, compared to an expected 102.19 million, with a 1.47% difference. The market reacted with a +2.58% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 19 analysts forecast an EPS of -0.23 USD, with revenue projected to reach 109.95 million USD, implying an -- of --% EPS, and increase of 6.04% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Immunocore Holdings plc - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Immunocore Holdings plc - ADR reported EPS of $0.00, beating estimates by 100%, and revenue of $103.69M, 1.47% above expectations.
How did the market react to Immunocore Holdings plc - ADR's Q3 2025 earnings?
The stock price moved up 2.58%, changed from $30.80 before the earnings release to $31.59 the day after.
When is Immunocore Holdings plc - ADR expected to report next?
The next earning report is scheduled for Feb 24, 2026.
What are the forecasts for Immunocore Holdings plc - ADR's next earnings report?
Based on 19
analysts, Immunocore Holdings plc - ADR is expected to report EPS of -$0.23 and revenue of $109.95M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement